Supernus to expand CNS portfolio with Sage Therapeutics acquisition
The acquisition allows Supernus to add ZURZUVAE, an FDA-approved oral treatment for postpartum depression, to its product lineup.
News
Teva, Fosun Pharma partner to develop anti-PD1-IL2 therapy TEV-56278
CSL secures FDA approval for Andembry to prevent HAE attacks
Mitsubishi, Astellas partner to support pharma startups in Japan
J&J unveils promising data for dual-targeting CAR T therapy
AstraZeneca, China-based CSPC partner to develop novel oral therapies
BioNTech to acquire mRNA drugmaker CureVac for up to $1.25bn
Moderna secures FDA expanded approval for mRESVIA RSV vaccine
